Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Uninterrupted treatment with novel oral anticoagulants (NOACs) during catheter ablation of atrial fibrillation (AF) is safe, reveals research presented today at EHRA EUROPACE – CARDIOSTIM 2015 by Dr Carsten Wunderlich, senior consultant in the Department of Invasive Electrophysiology, Heart Centre Dresden, Germany.1
Embargo: 24 June 2015 12:03 CEST (Paris)24 June 2015 11:03 BST (London)24 June 2015 06:03 EDT (New York)
Milan, Italy – 24 June 2015: Uninterrupted treatment with novel oral anticoagulants (NOACs) during catheter ablation of atrial fibrillation (AF) is safe, reveals research presented today at EHRA EUROPACE – CARDIOSTIM 2015 by Dr Carsten Wunderlich, senior consultant in the Department of Invasive Electrophysiology, Heart Centre Dresden, Germany.1 Continuation of NOAC therapy was not associated with periprocedural bleeding or thromboembolic complications.The joint meeting of the European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC) and Cardiostim is being held in Milan, Italy. The scientific programme is here Dr Wunderlich said: “Uninterrupted treatment with NOACs during ablation of AF is a subject of intense debate. We know that anticoagulation is essential in AF patients to prevent strokes. In patients with AF that does not respond to anti-arrhythmic drugs, catheter ablation with pulmonary vein isolation is a cornerstone of therapy but this procedure is associated with some bleeding risk. This has led to the recommendation to discontinue NOACs two days before the procedure in patients with normal renal function.”2But he added: “Interrupting NOACs during catheter ablation leaves patients vulnerable to thromboembolism. Two years ago in our centre this approach led to peripheral embolism in the leg of two patients and a stroke in one patient. At this point we decided not to interrupt NOAC therapy during catheter ablation in future patients.”This observational study included 549 consecutive patients with drug refractory AF who were scheduled for catheter ablation with pulmonary vein isolation at the Heart Centre Dresden. A total of 233 patients were taking a vitamin K antagonist and 316 patients were taking a NOAC. Patients continued to take their prescribed anticoagulation medication without missing any doses. After the procedure echocardiography was performed to exclude pericardial effusion and patients were followed up for six months.No patients in either group experienced a stroke or systemic embolism. There was one pericardial effusion in the vitamin K antagonist group and two in the NOAC group. Regarding access related complications, three NOAC patients had an arteriovenous fistula compared to one on vitamin K antagonists. False aneurysms (pseudoaneurysms) were experienced by seven patients on vitamin K antagonists and two on NOACs, while three NOAC patients had groin hematoma compared to four on vitamin K antagonists.“Our study suggests that NOACs can be continued during catheter ablation of AF without an increased risk of periprocedural bleeding or thromboembolism,” said Dr Wunderlich. “The number of pericardial effusions we observed was small. Importantly, pericardial effusions in the NOAC group did not require specialised treatment – we punctured them and sucked the blood out as normal. This should dispel the fears of physicians that NOACs act differently and there is no antidote.”He added: “The results of our observational study suggest that continuous NOACs are as good as continuous vitamin K antagonists during ablation of atrial fibrillation. Our study was conducted in a high volume centre with heart surgery on site and experienced physicians doing about 1 200 ablations a year. In clinical practice we do not stop NOACs before an ablation and this is a good approach for experienced centres but I would not recommend it for all hospitals. This is a single centre experience and a randomised trial is needed before firm conclusions can be drawn.”Dr Wunderlich said the data provided the impetus for a randomised trial. Patients would take their currently prescribed medication (vitamin K antagonist or NOAC) and be randomised to continuous or interrupted therapy during catheter ablation of AF. He said: “It is already accepted that uninterrupted vitamin K antagonists is associated with lower periprocedural complications than discontinuation of the drug and bridging with fractionated heparin. A randomised trial would give the evidence needed for uninterrupted NOAC therapy and put an end to the debate on this issue.”ENDS
1Dr Carsten Wunderlich will present the abstract ‘Ablation of atrial fibrillation with uninterrupted NOAC treatment during ablation of atrial fibrillation is not associated with severe peri- and postprocedural complications’ during the session ‘Complications of af ablation: avoidance, recognition and management’ which is held on 24 June at 11:00 in the Agora – Lecture Room2Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P; European Heart Rhythm Association. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013 May;15(5):625-651. doi: 10.1093/europace/eut083.
About EHRA EUROPACE – CARDIOSTIMEHRA EUROPACE – CARDIOSTIM is an established, international conference attracting key opinion leaders, well-recognised scientists, physicians, allied professionals and industry.About the European Heart Rhythm Association (EHRA)The European Society of Cardiology (ESC) represents more than 80 000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.The European Heart Rhythm Association (EHRA) is a registered branch of the ESC. Its aim is to improve the quality of life of the European population by reducing the impact of cardiac arrhythmias and reduce sudden cardiac death.Information for journalists attending EHRA EUROPACE - CARDIOSTIM 2015EHRA EUROPACE – CARDIOSTIM 2015 will be held 21 to 24 June in Milan, Italy at the MiCo Milano Congressi. The full scientific programme is available here• To register on-site please bring a valid press card or appropriate letter of assignment with proof of three recent published articles (cardiology or health-related, or referring to a previous ESC Event).• Press registration is not available to Industry or its Public Relations representatives, event management, marketing or communications representatives.
© 2017 European Society of Cardiology. All rights reserved